Search

Your search keyword '"Roca B."' showing total 425 results
Start Over Author "Roca B."
425 results on '"Roca B."'

3. Treatment of genitourinary syndrome of menopause: a sualitative study on patient perspectives on vaginal estrogen

Author

Dascanio, AM, primary, Zhang, H, additional, Malacarne Pape, D, additional, Rodriguez, V, additional, Yaskhi, G, additional, Janvier, D, additional, Chorna, ES, additional, Glass, M, additional, Immers, L, additional, Nussbaum, O, additional, Zweig, L, additional, Akbar, A, additional, Kasoff, M, additional, Roca, B, additional, Lleras, C, additional, Steinhart, A, additional, Grimes, CL, additional, and Andiman, SE, additional

Published
2024
Full Text
View/download PDF

7. Ageism and nursing students, past or reality?: a systematic review

Author

Allué-Sierra, L., Antón-Solanas, I., Rodríguez-Roca, B., Anguas-Gracia, A., Echániz-Serrano, E., Fernández-Rodrigo, M. T., Navas-Ferrer, C., Subirón-Valera, A. B., Urcola-Pardo, F., and Satústegui-Dordá, P. J.

Abstract

Objective: This systematic review aimed to summarise and update existing knowledge about ageism among nursing students through the following research question: what is the perception and attitudes of ageism among student nurses? Design: A systematic review of longitudinal and cross-sectional studies of ageism in nursing students was carried out. Data sources: The literature search was conducted in the scientific databases Pubmed and Scopus in February 2021. Review methods: After the screening process, 22 studies meeting the selection criteria were selected; 8 more were identified after manually searching the selected paper' reference lists. A total of 30 studies were included in the review. The JBI Critical Appraisal Checklists for Analytical Cross-Sectional studies and for Cohort Studies were used to appraise the articles' quality. Results: There was large variability in the manifestation of ageism among student nurses, as well as in the instruments used for assessment. Most of the articles analysed attitudes towards old age, the majority of which were positive. Being a female student, being on the final year of study and having regular contact or cohabitation with an older adult were three of the main determinants in the expression of positive attitudes towards the elderly. Conclusions: Our findings suggest that student nurses generally have positive attitudes towards old age, although ageist beliefs and discriminatory behaviours were identified and should be studied in greater depth. Training programs for future care professionals have a responsibility to educate from a non-stereotypical perspective based on current societal needs.

Published
2023

12. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort

Author

Teira, R, Diaz-Cuervo, H, Aragao, F, Munoz, J, Galindo, P, Merino, M, de la Fuente, B, Sepulveda, MA, Domingo, P, Garcia, J, Castano, M, Ribera, E, Geijo, P, Romero, A, Peraire, J, Deig, E, Roca, B, Martinez, E, Estrada, V, Montero, M, Berenguer, J, and Espinosa, N

Subjects
Cohort Studies, estimated glomerular filtration rate, Anti-HIV Agents, retrospective, HIV, tenofovir disoproxil fumarate, Humans, tenofovir alafenamide, HIV Infections, switch, emtricitabine, Glomerular Filtration Rate, Retrospective Studies
Abstract

Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, >= 1 follow-up measurement, >= 30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI

Published
2021

13. Palliative Sedation in Patients Hospitalized in Internal Medicine Departments

Author

Díez-Manglano J, Isasi de Isasmendi Pérez S, García Fenoll R, Sánchez LÁ, Formiga F, Giner Galvañ V, Dueñas C, Roca B, Estrada Díaz C, Casariego Vales E, and UDMIVI study researchers

Subjects
terminal care, Palliative sedation, internal medicine, palliative care
Abstract

Context. Palliative sedation is used to relieve end-of-life refractory symptoms. Objective. The objective of this study was to describe the use of palliative sedation in patients who die in internal medicine departments. Methods. An observational, cross-sectional, retrospective, and multicenter clinical audit study was conducted in 145 hospitals in Spain and Argentina. Each hospital included the first 10 patients who died in the internal medicine department, starting on December 1, 2015. Results. We included 1447 patients, and palliative sedation was administered to 701 patients (48.4%). Having a terminal illness (odds ratio [OR] 2.469, 95% CI 1.971-3.093, P < 0.001) and the length of hospital stay (OR 1.011, 95% CI 1.002-1.021, P = 0.017) were independently associated with the use of palliative sedation. Consent was granted by the families of 582 (83%) patients. The most common refractory symptom was dyspnea, and the most commonly used drugs for sedation were midazolam (77%) and morphine (89.7%). An induction dose was administered in 25.7% of the patients. Rescue doses were scheduled for 70% of the patients, and hydration was maintained in 49.5%. Pain was more common in patients with cancer, whereas dyspnea was more common in those without cancer. Rescue doses were used more often for the patients with cancer (77.8% vs. 67.7%, P = 0.015). Monitoring the palliative sedation with a scale was more frequent in the patients with cancer (23.7% vs. 14.3%, P = 0.008). Conclusions. Palliative sedation is used more often for terminal patients. There are differences in the administration of palliative sedation between patients with and without cancer. (C) 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Published
2020

14. Within subject variability of HDL-cholesterol in HIV-infected patients

Author

Roca B, Mendoza MA, and Roca M

Subjects
Within subject variability, lipids (amino acids, peptides, and proteins), HIV-infected patients, HDL-cholesterol
Abstract

Background and objective: Within-subject variability of cardiovascular risk factors may influence the development of cardiovascular disease. We aimed to improve knowledge on HDL-cholesterol variability and its clinical significance in HIV-infected patients, a population at high risk of cardiovascular disease. Methods: This was a cohort study to quantify the variability of HDL-cholesterol between two consecutive visits and to determine factors associated with such variability, in a group of HIV-infected patients. Results: A total of 307 patients were included, mean ? standard deviation of their age was 45.1 ? 8.5 years, and 225 of them (73.3%) were male. The absolute difference (after squaring and root squaring) of serum HDL-cholesterol level between the first and the second visit was 12.1 ? 9.2 mg/dL. In 65 patients (21.2%) the absolute value of the difference between both serum HDL-cholesterol level results were 20 mg/dL or higher. In a multivariable analysis the number of cigarettes smoked per day showed a significant, negative, correlation with the absolute difference in serum HDL-cholesterol level between the two visits (P = 0,009). Conclusions: Within-subject variability of HDL-cholesterol was substantial among our HIV-infected patients. Smoking was inversely correlated with such variability.

Published
2020

15. Factors Associated with Nonsuppression of HIV Infection in the Spanish VACH Cohort

Author

Roca B and Spanish Vach Cohort Grp

Subjects
HIV nonsuppression, virus diseases, HIV, Spanish VACH Cohort
Abstract

We aim to determine the prevalence of HIV nonsuppression and factors associated with it. This is a cross-sectional multicenter study carried out in January 2016 with data of the VACH Cohort, a registry participated by 23 hospitals from most regions of Spain. The prevalence of HIV nonsuppression, defined as HIV RNA >= 200 copies/mL, is documented. The possible association of HIV nonsuppression with sociodemographic and clinical variables is assessed with a logistic regression analysis. A total of 30,843 adult patients are included; 7,358 of them (23.86%) have nonsuppressed HIV. An association is found between nonsuppression of HIV and the following variables: lower body mass index, lower age of patients in their last registered visit, lower number of visits carried out during follow-up, lower last available CD4 cell count, higher age of patients at the time of their HIV infection diagnosis, higher lowest available CD4 cell count, higher highest available HIV RNA, enrolment in the Cohort in first years of the HIV epidemic, region of Spain where the patient is attended other than Andalusia, HIV risk factor other than sexual, occurrence of death during follow-up, hepatitis C coinfection, being a smoker, pertaining to groups A1 or A2 of the CDC groups classification, and not taking antiretroviral treatment,p < .001 in all cases. HIV nonsuppression is still common with the effective antiretroviral treatment nowadays available. HIV nonsuppression is associated with HIV risk factor other than sexual, hepatitis C coinfection, and being a smoker, among other factors.

Published
2020

22. Health-related quality of life of people living with HIV infection in Spain: a gender perspective

Author

Fumaz, C, Larranaga-Eguilegor, M, Mayordomo-Lopez, S, Gomez-Martinez, S, Gonzalez-Garcia, M, Ornellas, A, de Apodaca, M, Remor, E, Ballester-Arnal, R, Lopez-Zuniga, A, Santos-Miguel, I, Albiol-Soto, M, Ferrer-Lasala, M, Tuldra-Nino, A, Ferrando-Vilalta, R, Santamaria-Jauregui, J, Iribarren-Loyarte, J, de Apodaca, R, Pasquau-Liano, F, Tornero-Esteban, C, Roca, B, Canoves-Martinez, L, Lorenzo-Gonzalez, J, Ubillos-Landa, S, Ruzafa-Martinez, M, Aguirrezabal-Prado, A, Arnoso-Martinez, A, Molero, F, Nouvilas-Palleja, E, Perez-Garin, D, Sanjuan-Suarez, P, Gilllario, M, Madrigal-Vilchez, A, Castro-Calvo, J, Gil-Julia, B, Gimenez-Garcia, C, Ruiz-Palomino, E, and Spanish Grp Quality Life Improve

Subjects
health-related quality of life, gender differences, HIV/AIDS, physical health, mental health
Abstract

Studies exploring gender differences in health-related quality of life (HRQOL) of people living with HIV/AIDS (PLWHA) are scarce and contradictory. This study evaluated gender differences in HRQOL of 744 PLWHA with median (IQR) age 44 (37-48) years and HIV infection diagnosed 12 (5-20) years earlier. Results showed important differences between genders (p < .05). Better male physical health was related to being employed, not having economic worries, not receiving psychological support, not having injected drugs in past, low negative mood HIV-related, low HIV illness representation and internalized stigma, and high body image satisfaction and health behavior. For women, variables were fewer years since HIV diagnosis and low enacted stigma-personal experience of rejection. Mentally, variables in men were being employed, not having injected drugs, having a stable partner, high health behavior, use of problem-solving coping, personal autonomy and personal meaning. In women, better mental health was related to high CD4 cells, self-esteem and body image satisfaction, and negative mood HIV-related. Men and women coincided in absence of past opportunistic infections being related to better physical and mental health, and absence of side effects for physical health and low HIV-related stress and HIV illness representation for mental health. Our results highlight the need for detailed study of gender differences that identify the bio-psycho-socio inequalities that affect HRQOL.

Published
2019

23. Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors

Author

Teira, R, Espinosa, N, Gutierrez, MM, Montero, M, Martinez, E, Gonzalez, F, de Leon, FL, Tellez, F, Galindo, MJ, Peraire, J, Deig, E, Munoz-Sanchez, P, de la Fuente, B, Campoamor, M, Domingo, P, Puig, T, Ribera, E, Roca, B, Garcia, J, Castano, M, Mayorga, MI, Terron, A, Alvarez, A, Suarez-Lozano, I, Merino, L, Geijo, P, Belinchon, O, Sepulveda, MA, Estrada, V, Munoz-Sanz, A, Mateo, MG, Vilades, C, Castro, I, Lopez-Cortes, L, Mateos, F, and Grp Estudio VACH

Subjects
Human immunodeficiency virus, Epidemiology, Follow-up, Cohorts
Abstract

Objective: To determine the proportion of people infected by HIV or AIDS under follow-up in the VACH Cohort in 2012 who were lost to follow-up from 2013 to 2014, and to establish the sociodemographic features relating to this loss. Methods: We considered subjects with less than one recorded consultation per year studied to be lost to follow-up. We built logistic regression models to calculate the odds ratios (OR) and their 95% confidence intervals (95% CI), of the variables relating to loss to follow-up. Results: The overall percentage of losses to follow-up was 15.5% (95% CI 14.9-16-1). The variables associated with loss to follow up were: not receiving antiretroviral treatment (ART) (OR: 1.948, 95% CI: 1.651-2.298), being an immigrant (OR: 1.746; 95%Cl: 1.494-2.040), intravenous drug consumption being the mechanism for HIV transmission (OR: 1.498, 95% CI: 1.312-1.711), being unemployed (OR: 1.331; 95% CI: 1.179-1.503), being without a partner (OR: 1.948, 95% CI: 1.651-1.298), belonging to a low socioeconomic class (OR: 1.279; 95% Cl: 1.143-1.431), and being attended in a hospital with fewer than 1000 patients under follow-up (OR: 1.257, 95% CI: 1.121-1.457), as well as being under age and having spent less time under follow-up in the Cohort. Conclusions: 15.5% of the patients were lost to follow-up over a period of 2 years in the VACH Cohort. This was associated with a series of sociodemographic and epidemiological variables that it might be useful to identify to design initiatives targeting the populations most likely to abandon the circuits of care, and guide strategies towards achieving Objective 90-90-90. (C) 2018 Published by Elsevier Espana, S.L.U.

Published
2019

24. De novo acute heart failure: Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure

Author

Franco, J, Formiga, F, Corbella, X, Conde-Martel, A, Llacer, P, Rocha, P, Gorricho, G, Satue, J, Rangel, L, Manzano, L, Montero-Perez-Barquero, M, Anarte, L, Aramburu, O, Arevalo-Lorido, J, Carrascosa, S, Carrera, M, Cepeda, J, Cerqueiro, J, Davila, M, Diez-Manglano, J, Epelde, F, Garcia-Escriva, D, Franco, A, Lopez-Castellanos, G, Muela, A, Perez-Silvestre, J, Quesada, M, Roca, B, Ruiz-Ortega, R, Soler-Rangel, L, Trullas, J, and Grp Invest RICA

Subjects
New onset heart failure, Left ventricular ejection fraction, Clinical characteristics, Acute heart failure, Prognosis
Abstract

Introduction and objectives: Acute heart failure (AHF), can occur as decompensated chronic heart failure (HF) or as a first episode, "new onset". The aim of this study was to analyse the clinical characteristics and prognosis at one-year in a cohort of patients with new onset AHF. Methods: Prospective observational study of 3,550 patients with AHF. We compared patients with new onset HF with the others. Restricting the analysis to new onset AHF patients, we analysed the clinical characteristics, readmissions, mortality and impact of left ventricular ejection fraction on the prognosis. Results: A total of 1,105 (31%) patients fulfil the criteria for new onset AHF. These patients versus the rest, were younger, had a higher aetiology of hypertension and preserved left ventricular ejection fraction, less global comorbidity and better baseline overall functional status. After one year, mortality in new onset HF was less than chronic decompensated HF (15 vs. 27%; p

Published
2019

25. Health-related quality of life of people living with HIV infection in Spain: a gender perspective

Author

Fumaz, CR, Larranaga-Eguilegor, M, Mayordomo-Lopez, S, Gomez-Martinez, S, Gonzalez-Garcia, M, Ornellas, A, de Apodaca, MJFR, Remor, E, Ballester-Arnal, R, Lopez-Zuniga, AM, Santos-Miguel, I, Albiol-Soto, M, Ferrer-Lasala, MJ, Tuldra-Nino, A, Ferrando-Vilalta, R, Santamaria-Jauregui, JM, Iribarren-Loyarte, JA, de Apodaca, RFR, Pasquau-Liano, F, Tornero-Esteban, C, Roca, B, Canoves-Martinez, L, Lorenzo-Gonzalez, JF, Ubillos-Landa, S, Ruzafa-Martinez, M, Aguirrezabal-Prado, A, Arnoso-Martinez, A, Molero, F, Nouvilas-Palleja, E, Perez-Garin, D, Sanjuan-Suarez, P, Gilllario, MD, Madrigal-Vilchez, A, Castro-Calvo, J, Gil-Julia, B, Gimenez-Garcia, C, and Ruiz-Palomino, E

Subjects
health-related quality of life, gender differences, HIV/AIDS, physical health, mental health
Abstract

Studies exploring gender differences in health-related quality of life (HRQOL) of people living with HIV/AIDS (PLWHA) are scarce and contradictory. This study evaluated gender differences in HRQOL of 744 PLWHA with median (IQR) age 44 (37-48) years and HIV infection diagnosed 12 (5-20) years earlier. Results showed important differences between genders (p < .05). Better male physical health was related to being employed, not having economic worries, not receiving psychological support, not having injected drugs in past, low negative mood HIV-related, low HIV illness representation and internalized stigma, and high body image satisfaction and health behavior. For women, variables were fewer years since HIV diagnosis and low enacted stigma-personal experience of rejection. Mentally, variables in men were being employed, not having injected drugs, having a stable partner, high health behavior, use of problem-solving coping, personal autonomy and personal meaning. In women, better mental health was related to high CD4 cells, self-esteem and body image satisfaction, and negative mood HIV-related. Men and women coincided in absence of past opportunistic infections being related to better physical and mental health, and absence of side effects for physical health and low HIV-related stress and HIV illness representation for mental health. Our results highlight the need for detailed study of gender differences that identify the bio-psycho-socio inequalities that affect HRQOL.

Published
2019

30. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author

Rohner E., Butikofer L., Schmidlin K., Sengayi M., Maskew M., Giddy J., Garone D., Moore R. D., D'Souza G., Goedert J. J., Achenbach C., Gill M. J., Kitahata M. M., Patel P., Silverberg M. J., Castilho J., McGowan C., Chen Y. -M. A., Law M., Taylor N., Paparizos V., Bonnet F., Verbon A., Fatkenheuer G., Post F. A., Sabin C., Mocroft A., Le Moing V., Dronda F., Obel N., Grabar S., Spagnuolo V., Antinori A., Quiros-Roldan E., Mussini C., Miro J. M., Meyer L., Hasse B., Konopnicki D., Roca B., Barger D., Raben D., Clifford G. M., Franceschi S., Brockmeyer N., Chakraborty R., Egger M., Bohlius J., Judd A., Zangerle R., Touloumi G., Warszawski J., Dabis F., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Thorne C., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A. D., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., De Wit S., Costagliola D., D'Arminio-Monforte A., Chene G., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., Torti C., Van Der Valk M., Tanser F., Vinikoor M., MacEte E., Wood R., Stinson K., Fatti G., Phiri S., Chimbetete C., Malisita K., Eley B., Fritz C., Hobbins M., Kamenova K., Fox M., Prozesky H., Technau K., Sawry S., Benson C. A., Bosch R. J., Kirk G. D., Boswell S., Mayer K. H., Grasso C., Hogg R. S., Harrigan P. R., Montaner J. S. G., Yip B., Zhu J., Salters K., Gabler K., Buchacz K., Brooks J. T., Gebo K. A., Carey J. T., Rodriguez B., Horberg M. A., Thorne J. E., Rabkin C., Margolick J. B., Jacobson L. P., Klein M. B., Rourke S. B., Rachlis A. R., Cupido P., Hunter-Mellado R. F., Mayor A. M., Deeks S. G., Martin J. N., Saag M. S., Mugavero M. J., Willig J., Eron J. J., Napravnik S., Crane H. M., Drozd D. R., Haas D., Rebeiro P., Turner M., Bebawy S., Rogers B., Justice A. C., Dubrow R., Fiellin D., Gange S. J., Anastos K., Althoff K. N., McKaig R. G., Freeman A. M., Lent C., Van Rompaey S. E., Morton L., McReynolds J., Lober W. B., Abraham A. G., Lau B., Zhang J., Jing J., Modur S., Wong C., Hogan B., Desir F., Liu B., You B., Cahn P., Cesar C., Fink V., Sued O., Dell'Isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., De Boni R., Wagner S. C., Friedman R., Moreira R., Pinto J., Ferreira F., Maia M., De Menezes Succi R. C., MacHado D. M., De Fatima Barbosa Gouvea A., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Rouzier V., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Mejia F., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Duda S. N., Maruri F., Vansell H., Ly P. S., Khol V., Zhang F. J., Zhao H. X., Han N., Lee M. P., Li P. C. K., Lam W., Chan Y. T., Kumarasamy N., Saghayam S., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Merati T. P., Wirawan D. N., Yuliana F., Yunihastuti E., Imran D., Widhani A., Tanuma J., Oka S., Nishijima T., Choi J. Y., Na S., Kim J. M., Sim B. L. H., Gani Y. M., David R., Kamarulzaman A., Syed Omar S. F., Ponnampalavanar S., Azwa I., Ditangco R., Uy E., Bantique R., Wong W. W., Ku W. W., Wu P. C., Ng O. T., Lim P. L., Lee L. S., Ohnmar P. S., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Sungkanuparph S., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Kotarathititum W., Praparattanapan J., Kantipong P., Kambua P., Ratanasuwan W., Sriondee R., Nguyen K. V., Bui H. V., Nguyen D. T. H., Nguyen D. T., Cuong D. D., An N. V., Luan N. T., Sohn A. H., Ross J. L., Petersen B., Cooper D. A., Law M. G., Jiamsakul A., Boettiger D. C., Ellis D., Bloch M., Agrawal S., Vincent T., Allen D., Smith D., Rankin A., Baker D., Templeton D. J., Jackson E., McCallum K., Ryder N., Sweeney G., Cooper D., Carr A., MacRae K., Hesse K., Finlayson R., Gupta S., Langton-Lockton J., Shakeshaft J., Brown K., Idle S., Arvela N., Varma R., Lu H., Couldwell D., Eswarappa S., Smith D. E., Furner V., Cabrera G., Fernando S., Cogle A., Lawrence C., Mulhall B., Boyd M., Petoumenos K., Puhr R., Huang R., Han A., Gunathilake M., Payne R., O'Sullivan M., Croydon A., Russell D., Cashman C., Roberts C., Sowden D., Taing K., Marshall P., Orth D., Youds D., Rowling D., Latch N., Warzywoda E., Dickson B., Donohue W., Moore R., Edwards S., Boyd S., Roth N. J., Lau H., Read T., Silvers J., Zeng W., Hoy J., Watson K., Bryant M., Price S., Woolley I., Giles M., Korman T., Williams J., Nolan D., Allen A., Guelfi G., Mills G., Wharry C., Raymond N., Bargh K., Templeton D., Medical Microbiology & Infectious Diseases, Global Health, Infectious diseases, APH - Aging & Later Life, AII - Infectious diseases, APH - Global Health, Graduate School, APH - Digital Health, APH - Personalized Medicine, Bohlius, Julia, Cohere In, Eurocoord, Castagna, Antonella, Rohner, E, Butikofer, L, Schmidlin, K, Sengayi, M, Maskew, M, Giddy, J, Garone, D, Moore, R, D'Souza, G, Goedert, J, Achenbach, C, Gill, M, Kitahata, M, Patel, P, Silverberg, M, Castilho, J, Mcgowan, C, Chen, Y, Law, M, Taylor, N, Paparizos, V, Bonnet, F, Verbon, A, Fatkenheuer, G, Post, F, Sabin, C, Mocroft, A, Le Moing, V, Dronda, F, Obel, N, Grabar, S, Spagnuolo, V, Antinori, A, Quiros-Roldan, E, Mussini, C, Miro, J, Meyer, L, Hasse, B, Konopnicki, D, Roca, B, Barger, D, Raben, D, Clifford, G, Franceschi, S, Brockmeyer, N, Chakraborty, R, Egger, M, Bohlius, J, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, De Wit, S, Costagliola, D, D'Arminio-Monforte, A, Chene, G, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Torti, C, Van Der Valk, M, Tanser, F, Vinikoor, M, Macete, E, Wood, R, Stinson, K, Fatti, G, Phiri, S, Chimbetete, C, Malisita, K, Eley, B, Fritz, C, Hobbins, M, Kamenova, K, Fox, M, Prozesky, H, Technau, K, Sawry, S, Benson, C, Bosch, R, Kirk, G, Boswell, S, Mayer, K, Grasso, C, Hogg, R, Harrigan, P, Montaner, J, Yip, B, Zhu, J, Salters, K, Gabler, K, Buchacz, K, Brooks, J, Gebo, K, Carey, J, Rodriguez, B, Horberg, M, Thorne, J, Rabkin, C, Margolick, J, Jacobson, L, Klein, M, Rourke, S, Rachlis, A, Cupido, P, Hunter-Mellado, R, Mayor, A, Deeks, S, Martin, J, Saag, M, Mugavero, M, Willig, J, Eron, J, Napravnik, S, Crane, H, Drozd, D, Haas, D, Rebeiro, P, Turner, M, Bebawy, S, Rogers, B, Justice, A, Dubrow, R, Fiellin, D, Gange, S, Anastos, K, Althoff, K, Mckaig, R, Freeman, A, Lent, C, Van Rompaey, S, Morton, L, Mcreynolds, J, Lober, W, Abraham, A, Lau, B, Zhang, J, Jing, J, Modur, S, Wong, C, Hogan, B, Desir, F, Liu, B, You, B, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, De Boni, R, Wagner, S, Friedman, R, Moreira, R, Pinto, J, Ferreira, F, Maia, M, De Menezes Succi, R, Machado, D, De Fatima Barbosa Gouvea, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Rouzier, V, Marcelin, A, Perodin, C, Luque, M, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Mejia, F, Carriquiry, G, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Giganti, M, Duda, S, Maruri, F, Vansell, H, Ly, P, Khol, V, Zhang, F, Zhao, H, Han, N, Lee, M, Li, P, Lam, W, Chan, Y, Kumarasamy, N, Saghayam, S, Ezhilarasi, C, Pujari, S, Joshi, K, Gaikwad, S, Chitalikar, A, Merati, T, Wirawan, D, Yuliana, F, Yunihastuti, E, Imran, D, Widhani, A, Tanuma, J, Oka, S, Nishijima, T, Choi, J, Na, S, Kim, J, Sim, B, Gani, Y, David, R, Kamarulzaman, A, Syed Omar, S, Ponnampalavanar, S, Azwa, I, Ditangco, R, Uy, E, Bantique, R, Wong, W, Ku, W, Wu, P, Ng, O, Lim, P, Lee, L, Ohnmar, P, Avihingsanon, A, Gatechompol, S, Phanuphak, P, Phadungphon, C, Kiertiburanakul, S, Sungkanuparph, S, Chumla, L, Sanmeema, N, Chaiwarith, R, Sirisanthana, T, Kotarathititum, W, Praparattanapan, J, Kantipong, P, Kambua, P, Ratanasuwan, W, Sriondee, R, Nguyen, K, Bui, H, Nguyen, D, Cuong, D, An, N, Luan, N, Sohn, A, Ross, J, Petersen, B, Cooper, D, Jiamsakul, A, Boettiger, D, Ellis, D, Bloch, M, Agrawal, S, Vincent, T, Allen, D, Smith, D, Rankin, A, Baker, D, Templeton, D, Jackson, E, Mccallum, K, Ryder, N, Sweeney, G, Carr, A, Macrae, K, Hesse, K, Finlayson, R, Gupta, S, Langton-Lockton, J, Shakeshaft, J, Brown, K, Idle, S, Arvela, N, Varma, R, Lu, H, Couldwell, D, Eswarappa, S, Furner, V, Cabrera, G, Fernando, S, Cogle, A, Lawrence, C, Mulhall, B, Boyd, M, Petoumenos, K, Puhr, R, Huang, R, Han, A, Gunathilake, M, Payne, R, O'Sullivan, M, Croydon, A, Russell, D, Cashman, C, Roberts, C, Sowden, D, Taing, K, Marshall, P, Orth, D, Youds, D, Rowling, D, Latch, N, Warzywoda, E, Dickson, B, Donohue, W, Edwards, S, Boyd, S, Roth, N, Lau, H, Read, T, Silvers, J, Zeng, W, Hoy, J, Watson, K, Bryant, M, Price, S, Woolley, I, Giles, M, Korman, T, Williams, J, Nolan, D, Allen, A, Guelfi, G, Mills, G, Wharry, C, Raymond, N, and Bargh, K

Subjects
Male, viruses, HIV Infections, Men who have sex with men, Cohort Studies, 0302 clinical medicine, Risk Factors, Antiretroviral therapy, Cohort study, HIV, Kaposi sarcoma, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, HIV-1, Humans, Middle Aged, Sarcoma, Kaposi, Viral Load, Young Adult, 030212 general & internal medicine, Articles and Commentaries, Incidence (epidemiology), Hazard ratio, virus diseases, Sarcoma, 3. Good health, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, Coinfection, Microbiology (medical), antiretroviral therapy, 610 Medicine & health, Kaposi, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 360 Social problems & social services, medicine, cohort study, business.industry, medicine.disease, Confidence interval, business, Demography
Abstract

Background We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. Methods We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). Results We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were

Published
2017
Full Text
View/download PDF

31. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

Author

Bouteloup V., Sabin C., Mocroft A., Gras L., Pantazis N., Le Moing V., d'Arminio Monforte A., Mary-Krause M., Roca B., Miro J. M., Battegay M., Brockmeyer N., Berenguer J., Morlat P., Obel N., De Wit S., Fatkenheuer G., Zangerle R., Ghosn J., Perez-Hoyos S., Campbell M., Prins M., Chene G., Meyer L., Dorrucci M., Torti C., Thiebaut R., Touloumi G., Warszawski J., Dabis F., Leport C., Wittkop L., Reiss P., Wit F., Bucher H., Gibb D., Amo J. D., Thorne C., Kirk O., Stephan C., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., Prieto L., Conejo P. R., Soriano-Arandes A., Rauch A., Mussini C., Tookey P., Casabona J., Castagna A., Deborah Konopnick, Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., Costagliola D., del Amo J., Raben D., Judd A., Barger D., Colin C., Schwimmer C., Termote M., Friis-Moller N., Kjaer J., Brandt R. S., Bohlius J., Cozzi-Lepri A., Davies M. -A., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., van der Valk M., Wyss N., AII - Infectious diseases, APH - Global Health, Infectious diseases, APH - Aging & Later Life, Global Health, Bouteloup, V, Sabin, C, Mocroft, A, Gras, L, Pantazis, N, Le Moing, V, d'Arminio Monforte, A, Mary-Krause, M, Roca, B, Miro, Jm, Battegay, M, Brockmeyer, N, Berenguer, J, Morlat, P, Obel, N, De Wit, S, Fätkenheuer, G, Zangerle, R, Ghosn, J, Pérez-Hoyos, S, Campbell, M, Prins, M, Chêne, G, Dorrucci, M, Torti, C, Thiébaut, R, the Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord, Castagna, Antonella, Miro, J, Fatkenheuer, G, Perez-Hoyos, S, Chene, G, Meyer, L, Thiebaut, R, Touloumi, G, Warszawski, J, Dabis, F, Leport, C, Wittkop, L, Reiss, P, Wit, F, Bucher, H, Gibb, D, Amo, J, Thorne, C, Kirk, O, Stephan, C, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Rauch, A, Mussini, C, Tookey, P, Casabona, J, Castagna, A, Deborah, K, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, Costagliola, D, del Amo, J, Raben, D, Judd, A, Barger, D, Colin, C, Schwimmer, C, Termote, M, Friis-Moller, N, Kjaer, J, Brandt, R, Bohlius, J, Cozzi-Lepri, A, Davies, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, van der Valk, M, Wyss, N, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Research Department of Infection and Population Health [London], University College of London [London] (UCL), Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), Department of Hygiene, Epidemiology and Medical Statistics [Athens], University of Athens Medical School [Athens], Université de Montpellier (UM), Università degli Studi di Milano [Milano] (UNIMI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital General De Castellon, Clinical and experimental neuroimmunology [IDIBAPS], Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Hospital Basel [Basel], Ruhr-Universität Bochum [Bochum], Hospital General Universitario 'Gregorio Marañón' [Madrid], Hôpital Saint-André, University of Copenhagen = Københavns Universitet (KU), Université libre de Bruxelles (ULB), University Hospital of Cologne [Cologne], Universität Innsbruck [Innsbruck], Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universitat Autònoma de Barcelona (UAB), University of Illinois at Urbana-Champaign [Urbana], University of Illinois System, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Istituto Superiore di Sanita [Rome], Università degli Studi 'Magna Graecia' di Catanzaro [Catanzaro, Italie] (UMG), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli Studi di Milano = University of Milan (UNIMI), University of Copenhagen = Københavns Universitet (UCPH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Istituto Superiore di Sanità (ISS), Università degli Studi 'Magna Graecia' di Catanzaro = University of Catanzaro (UMG), Laboratoire de Météorologie Dynamique (UMR 8539) (LMD), Département des Géosciences - ENS Paris, École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS)-École des Ponts ParisTech (ENPC)-École polytechnique (X)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), CRAHI-UPC, Edifici NEXUS 104-106, Calle Gran Capità 2-4, 08034 Barcelona, Spain, affiliation inconnue, Pork CRC Roseworthy, Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI), Laboratoire Evolution, Génomes et Spéciation (LEGS), and Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, CD4-Positive T-Lymphocytes, Male, Pediatrics, Percentile, longitudinal data, [SDV]Life Sciences [q-bio], CD4 response, HIV monitoring, antiretroviral treatment monitoring, longitudinal data, HIV Infections, Cohort Studies, 0302 clinical medicine, antiretroviral treatment monitoring, CD4 response, HIV monitoring, Adolescent, Adult, Aged, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Monitoring, Europe, Female, HIV-1, Humans, Middle Aged, Treatment Outcome, Viral Load, Young Adult, Interquartile range, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], Epidemiology, HIV Infection, Pharmacology (medical), 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Health Policy, virus diseases, 3. Good health, Infectious Diseases, CD4-Positive T-Lymphocyte, Cohort, Viral load, Human, Cart, medicine.medical_specialty, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), medicine, business.industry, medicine.disease, 030112 virology, Antiretroviral therapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Anti-Retroviral Agent, Cohort Studie, business
Abstract

Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay ‘on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

Published
2017
Full Text
View/download PDF

32. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author

De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S., De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., and Yerly S.

Abstract

Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir.

Published
2016

33. Sarcoidosis presenting with acute dacryoadenitis

Author

Roca M, Moro G, Broseta R, and Roca B

Subjects
Sarcoidosis, dacryoadenitis, parotitis, Sarcoidosis, hemic and lymphatic diseases, parotitis, dacryoadenitis
Abstract

Sarcoidosis is a systemic inflammatory disorder, pathologically characterized by noncaseating epithelioid granulomas. We report a case of the disease that presented with acute dacryoadenitis followed by acute parotitis.

Published
2018

34. Non-Hodgkin lymphoma risk in adults living with HIV across five continents The AIDS-defining Cancer Project Working Group of leDEA and COHERE in EuroCoord

Author

Rohner, E, Butikofer, L, Schmidlin, K, Sengayi, M, Maskew, M, Giddy, J, Moore, RD, Goedert, JJ, Gill, MJ, Silverberg, MJ, Patel, P, Castilho, J, Hoy, J, Sohn, A, Bani-Sadr, F, Taylor, N, Paparizos, V, Le Moing, V, Bonnet, F, Verbon, Annelies, Vehreschild, J J, Post, FA, Sabin, C, Mocroft, A, Dronda, F, Obel, N, Grabar, S, Spagnuolo, V, Antinori, A, Quiros-Rol-Dan, E, Mussini, C, Miro, JM, Meyer, L, Hasse, B, Konopnicki, D, Roca, B, Boue, F, Barger, D, Raben, D, Clifford, GM, Franceschi, S, Brockmeyer, N, Egger, M, Bohlius, J, and Medical Microbiology & Infectious Diseases

Subjects
SDG 3 - Good Health and Well-being, antiretroviral therapy, cohort study, HIV, incidence rates, non-Hodgkin lymphoma
Published
2018

35. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients

Author

Rodríguez-Pintó, I. Espinosa, G. Erkan, D. Shoenfeld, Y. Cervera, R. Piette, J.C. Jacek, M. Roca, B. Tektonidou, M. Moutsopoulos, H. Boffa, J. Chapman, J. Stojanovich, L. Veloso, M.P. Praprotnik, S. Traub, B. Levy, R. Daryl, T. Tan, D. Boffa, M.C. Makatsaria, A. Ruano, M. Allievi, A. You, W. Khamastha, M. Hughes, S. Nilzete, L. Menendez Suso, J. Pacheco, J. Boriotti, M.F. Dias, C. Pangtey, G. Miller, S. Policepatil, S. Larissa, L. Marjatta, S. Carolyn, S. Noortje, T. Reiner, K. Arteaga, S. Leilani, T. Langsford, D. Niedzwiecki, M. Queyrel, V. Moroti-Constantinescu, R. Romero, C. Jeremic, K. Urbano, A. Hurtado-García, R. Kumar Das, A. Costedoat-Chalumeau, N. Yngvar, F. Gomez-Puerta, J.A. de Meigs, E. Smith, J.P. Zakharova, E. Nayer, A. Douglas, W. Lyndsey, R. Blanco, V. Vicent, C. Natalya, K. Damian, L. Valentini, E. Giula, B. Casal Moura, M. Loperena, O.A. Susan, Y.R. Imbert, G.G. Almasri, H. Hospach, T. Mouna, B. Robles, A. Wilson, H. Guisado, P. Ruiz, R. Rodriguez, J. CAPS Registry Project Group

Abstract

Objectives. The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry. Methods. Patients from the CAPS Registry were grouped based on their treatments: triple therapy; drugs included in the triple therapy but in different combinations; and none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups. Results. The CAPS Registry cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 54 episodes (10.3%), a total of 471 patients with CAPS were included [mean (S.D.) age 38.5 years (17); 68.2% female primary APS patients 62%]. Overall, 174 (36.9%) patients died. Triple therapy was prescribed in 189 episodes (40.1%), other combinations in 270 (57.3%) and none of those treatments in 12 episodes (2.5%); the mortality rate in the three groups was 28.6, 41.1 and 75%, respectively. Triple therapy was positively associated with a higher chance of survival when compared with non-treatment [adjusted odds ratio (OR) = 9.7, 95% CI: 2.3, 40.6] or treatment with other combinations of drugs included in the triple therapy (adjusted OR = 1.7, 95% CI: 1.2, 2.6). No statistical differences were found between patients that received triple therapy with plasma exchange or IVIGs (P = 0.92). Conclusion. Triple therapy is independently associated with a higher survival rate among patients with CAPS. © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Published
2018

36. Insuficiencia cardiaca aguda de novo: características clínicas y mortalidad al año en el Registro Español de Insuficiencia Cardiaca Aguda

Author

Franco, Jonathan, primary, Formiga, Francesc, additional, Corbella, Xavier, additional, Conde-Martel, Alicia, additional, Llácer, Pau, additional, Álvarez Rocha, Pablo, additional, Ormaechea Gorricho, Gabriela, additional, Satué, José, additional, Soler Rangel, Llanos, additional, Manzano, Luis, additional, Montero-Pérez-Barquero, Manuel, additional, Anarte, L., additional, Aramburu, O., additional, Arévalo-Lorido, J.C., additional, Carrascosa, S., additional, Carrera, M., additional, Cepeda, J.M., additional, Cerqueiro, J.M., additional, Conde-Martel, A., additional, Dávila, M.F., additional, Díez-Manglano, J., additional, Epelde, F., additional, Formiga, F., additional, Franco, J., additional, García-Escrivá, D., additional, González Franco, A., additional, Llàcer, P., additional, López-Castellanos, G., additional, Manzano, L., additional, Montero-Pérez-Barquero, M., additional, Muela, A., additional, Pérez-Silvestre, J., additional, Quesada, M.A., additional, Roca, B., additional, Ruíz-Ortega, R., additional, Satué, J.A., additional, Soler-Rangel, L., additional, and Trullàs, J.C., additional

Published
2019
Full Text
View/download PDF

37. De novo acute heart failure: Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure

Author

Franco, Jonathan, primary, Formiga, Francesc, additional, Corbella, Xavier, additional, Conde-Martel, Alicia, additional, Llácer, Pau, additional, Álvarez Rocha, Pablo, additional, Ormaechea Gorricho, Gabriela, additional, Satué, José, additional, Soler Rangel, Llanos, additional, Manzano, Luis, additional, Montero-Pérez-Barquero, Manuel, additional, Anarte, L., additional, Aramburu, O., additional, Arévalo-Lorido, J.C., additional, Carrascosa, S., additional, Carrera, M., additional, Cepeda, J.M., additional, Cerqueiro, J.M., additional, Conde-Martel, A., additional, Dávila, M.F., additional, Díez-Manglano, J., additional, Epelde, F., additional, Formiga, F., additional, Franco, J., additional, García-Escrivá, D., additional, González Franco, A., additional, Llàcer, P., additional, López-Castellanos, G., additional, Manzano, L., additional, Montero-Pérez-Barquero, M., additional, Muela, A., additional, Pérez-Silvestre, J., additional, Quesada, M.A., additional, Roca, B., additional, Ruíz-Ortega, R., additional, Satué, J.A., additional, Soler-Rangel, L., additional, and Trullàs, J.C., additional

Published
2019
Full Text
View/download PDF

38. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author

De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S., De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, University of Zurich, De Luca, Andrea, Santoro, Mm, Günthard, Hf, Brockmeyer, Nh, Perno, Cf, Schülter, E, on behalf of CHAIN and COHERE in, Eurocoord, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, and Medical Microbiology and Infection Prevention

Subjects
0301 basic medicine, Oncology, Male, Enfuvirtide, Genotyping Techniques, HIV Infections, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, 0302 clinical medicine, HIV Protease, Genotype, 2736 Pharmacology (medical), Medicine, HIV Infection, Pharmacology (medical), 030212 general & internal medicine, Non-U.S. Gov't, Darunavir, Aged, 80 and over, Microbial Sensitivity Test, Medicine (all), Research Support, Non-U.S. Gov't, Proteolytic enzymes, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Prognosis, Europe, 3004 Pharmacology, Treatment Outcome, Infectious Diseases, Mutation (genetic algorithm), Female, Human, medicine.drug, Microbiology (medical), Adult, medicine.medical_specialty, Adolescent, Pharmacology, Prognosi, Anti-HIV Agents, 610 Medicine & health, Microbial Sensitivity Tests, Settore MED/17 - MALATTIE INFETTIVE, Research Support, Article, 03 medical and health sciences, Young Adult, Internal medicine, Linear regression, Drug Resistance, Viral, Journal Article, Humans, Aged, Receiver operating characteristic, business.industry, Anti-HIV Agent, 2725 Infectious Diseases, Raltegravir, 030112 virology, Virology, HIV Darunavir, Mutation, HIV-1, genotypic, Genotyping Technique, business
Abstract

Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir.

Published
2016

39. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naive patients

Author

Bouteloup, V. Sabin, C. Mocroft, A. Gras, L. Pantazis, N. Le Moing, V. d'Arminio Monforte, A. Mary-Krause, M. and Roca, B. Miro, J. M. Battegay, M. Brockmeyer, N. and Berenguer, J. Morlat, P. Obel, N. De Wit, S. and Faetkenheuer, G. Zangerle, R. Ghosn, J. Perez-Hoyos, S. and Campbell, M. Prins, M. Chene, G. Meyer, L. Dorrucci, M. and Torti, C. Thiebaut, R. Stand Reference Distribution CD4 R

Abstract

ObjectivesThe aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. MethodsAll patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load 50 HIV-1 RNA copies/mL at 6 months ( 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. ResultsA total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/L. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/L. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of 100 cells/mL is generally required in order that patients stay on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. ConclusionsReference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

Published
2017

42. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naive patients

Author

Bouteloup, V., Sabin, C., Mocroft, A., Gras, L., Pantazis, N., Le Moing, V., d'Arminio Monforte, A., Mary-Krause, M., Roca, B., Miro, J. M., Battegay, M., Brockmeyer, N., Berenguer, J., Morlat, P., Obel, N., De Wit, S., Faetkenheuer, G., Zangerle, R., Ghosn, J., Perez-Hoyos, S., Campbell, M., Prins, M., Chene, G., Meyer, L., Dorrucci, M., Torti, C., Thiebaut, R., Bouteloup, V., Sabin, C., Mocroft, A., Gras, L., Pantazis, N., Le Moing, V., d'Arminio Monforte, A., Mary-Krause, M., Roca, B., Miro, J. M., Battegay, M., Brockmeyer, N., Berenguer, J., Morlat, P., Obel, N., De Wit, S., Faetkenheuer, G., Zangerle, R., Ghosn, J., Perez-Hoyos, S., Campbell, M., Prins, M., Chene, G., Meyer, L., Dorrucci, M., Torti, C., and Thiebaut, R.

Abstract

ObjectivesThe aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. MethodsAll patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load 50 HIV-1 RNA copies/mL at 6 months ( 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. ResultsA total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/L. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/L. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of 100 cells/mL is generally required in order that patients stay on track' (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. ConclusionsReference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.

Published
2017

43. Improved weighted darunavir genotypic mutation score predicting treatment response for HIV-1 subtype B and non-B infected patients receiving darunavir in a salvage regimen

Author

Luca, A., Flandre, P., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Churchill, D., Wit, S., Dunn, D., Fuchs, W., Garcia, F., Guenthard, H., Imaz, A., Kordossis, T., Mussini, C., Obel, N., Roca, B., Santoro, M. M., Schuelter, E., Torti, C., Sighem, A., Wensing, A. M., Linda Wittkop, Zangerle, R., Zazzi, M., Descamps, D., De Luca, A., Flandre, P., Castagna, Antonella, Ceccherini Silberstein, F., Cozzi Lepri, A., Churchill, D., De Wit, S., Dunn, D., Fuchs, W., Garcia, F., Guenthard, H., Imaz, A., Kordossis, T., Mussini, C., Obel, N., Roca, B., Santoro, M. M., Schuelter, E., Torti, C., van Sighem, A., Wensing, A. M., Wittkop, L., Zangerle, R., Zazzi, M., and Descamps, D.

Published
2014

45. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author

De Luca, A. Flandre, P. Dunn, D. Zazzi, M. Wensing, A. Santoro, M.M. Günthard, H.F. Wittkop, L. Kordossis, T. Garcia, F. Castagna, A. Cozzi-Lepri, A. Churchill, D. De Wit, S. Brockmeyer, N.H. Imaz, A. Mussini, C. Obel, N. Perno, C.F. Roca, B. Reiss, P. Schülter, E. Torti, C. van Sighem, A. Zangerle, R. Descamps, D. Mocroft, A. Kirk, O. Sabin, C. Casadi, W. Casabona, J. Miró, J.M. Touloumi, G. Garrido, M. Teira, R. Wit, F. Warszawski, J. Meyer, L. Dabis, F. Krause, M.M. Ghosn, J. Leport, C. Prins, M. Bucher, H. Gibb, D. Fätkenheuer, G. del Amo, J. Thorne, C. Stephan, C. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Noguera-Julian, A. Antinori, A. d'Arminio Monforte, A. Prieto, L. Conejo, P.R. Soriano-Arandes, A. Battegay, M. Kouyos, R. Tookey, P. Konopnick, D. Goetghebuer, T. Sönnerborg, A. Haerry, D. Costagliola, D. Raben, D. Chêne, G. Ceccherini-Silberstein, F. Günthard, H. Judd, A. Barger, D. Schwimmer, C. Termote, M. Campbell, M. Frederiksen, C.M. Friis-Møller, N. Kjaer, J. Brandt, R.S. Berenguer, J. Bohlius, J. Bouteloup, V. Davies, M.-A. Dorrucci, M. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Monge, S. Nakagawa, F. Paredes, R. Phillips, A. Puoti, M. Schomaker, M. Smit, C. Sterne, J. Thiebaut, R. van der Valk, M. Wyss, N. Aubert, V. Battegay, M. Bernasconi, E. Böni, J. Burton-Jeangros, C. Calmy, A. Cavassini, M. Dollenmaier, G. Egger, M. Elzi, L. Fehr, J. Fellay, J. Furrer, H. Fux, C.A. Gorgievski, M. Günthard, H. Haerry, D. Hasse, B. Hirsch, H.H. Hoffmann, M. Hösli, I. Kahlert, C. Kaiser, L. Keiser, O. Klimkait, T. Kouyos, R. Kovari, H. Ledergerber, B. Martinetti, G. Martinez de Tejada, B. Metzner, K. Müller, N. Nadal, D. Nicca, D. Pantaleo, G. Rauch, A. Regenass, S. Rickenbach, M. Rudin, C. Schöni-Affolter, F. Schmid, P. Schüpbach, J. Speck, R. Tarr, P. Telenti, A. Trkola, A. Vernazza, P. Weber, R. Yerly, S. CHAIN COHERE in EuroCoord

Abstract

Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir. © The Author 2016.

Published
2016

47. Primär extramedulläres Plasmozytom der Mamma

Author

Hetterich, M, additional, Roca, B, additional, Ortmann, O, additional, Seitz, S, additional, Schüler-Toprak, S, additional, Evert, M, additional, Wiesinger, H, additional, Herr, W, additional, Mayer, S, additional, and Rosenwald, A, additional

Published
2017
Full Text
View/download PDF

50. Spanish consensus on premature menopause

Author

Mendoza N, Julia MD, Galliano D, Coronado P, Diaz B, Fontes J, Gallo JL, Garcia A, Guinot M, Munnamy M, Roca B, Sosa M, Tomas J, Llaneza P, and Sanchez-Borrego R

Subjects
Premature menopause, Osteoporosis, Fertility treatments, Primary ovarian insufficiency, Fertility preservation, Hormonal therapy
Abstract

Introduction: While we recognise that the term premature menopause is more accepted by most nonspecialist health care providers and by the general population, 'primary ovarian insufficiency' (POI) is currently considered the most apposite term to explain the loss of ovarian function, because it better explains the variability of the clinical picture, does not specify definitive failure, and highlights the specific ovarian source. Its pathogenesis involves a congenital reduction in the number of primordial follicles, poor follicle recruitment, or accelerated follicular apoptosis. However, its cause is unknown in most cases. Aim: This guide analyses the factors associated with the diagnosis and treatment of POI and provides recommendations on the most appropriate diagnostic and therapeutic measures for women under 40 years of age who experience POI. Methodology: A panel of experts from various Spanish scientific societies related to POI (Spanish Menopause Society, Spanish Fertility Society, and Spanish Contraception Society) met to reach a consensus on these issues. Results: Hormonal therapy (HT) is considered the treatment of choice to alleviate the symptoms of hypoestrogenism and to prevent long-term consequences. We suggest that HT should be continued until at least age 51, the average age at natural menopause. The best treatment to achieve pregnancy is oocyte/embryo donation. If a patient is to undergo treatment that will reduce her fertility, she should be informed of this issue and the available techniques to preserve ovarian function, mainly vitrification of oocytes. (C) 2014 Elsevier Ireland Ltd All rights reserved.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results